Chiltern International Ltd. Appoints Glenn Kerkhof As CEO

LONDON, Aug. 22 /PRNewswire/ -- Chiltern International, a leading independent clinical Contract Research Organization (CRO), announced today it has appointed Glenn Kerkhof as Chief Executive Officer.

Kerkhof has more than 13 years of management experience in the pharmaceutical services industry. He joins Chiltern from Charles River Laboratories, where he served as the Vice President of Global Operations for Clinical Services and was responsible for operating a business unit comprised of more than 1,100 people in 20 countries. Prior to Charles River, Kerkhof served at Inveresk Research Group as the Vice President of Operations for Clinical Services in Europe and Asia Pacific.

“Glenn brings to Chiltern strong leadership, senior operational experience and extensive knowledge of the pharmaceutical services industry from serving as the head of global clinical operations at Charles River Laboratories and Inveresk Research Group, two leading international CROs,” said Nick Thornton, Vice Chairman of Chiltern International. “Glenn’s expertise in global clinical services will help Chiltern maintain high standards of quality and leverage considerable opportunities for growth around the world.”

“This is an exciting opportunity to join a leading independent CRO with 25 years of history and a strong reputation for quality in international clinical services,” said Kerkhof. “Chiltern today is well-positioned to capitalize on the growing market for high-quality, international services in Phase I to Phase IV clinical trials. I look forward to working with Nick and the very talented management team at Chiltern.”

Kerkhof’s appointment follows the recent acquisition of Chiltern International by Czura Thornton, a private investment group led by Antony Czura and Nick Thornton.

About Chiltern International

Established in the UK in 1982, Chiltern is one of the largest independent contract research organizations in the world and has extensive experience of running international Phase I to Phase IV clinical trials across a broad therapeutic range with a wide variety of clients. Chiltern employs more than 850 people worldwide, with locations in the UK, France, Germany, Italy, Spain, Poland, the Czech Republic, Ukraine, India, South Africa and across the US. Chiltern provides Clinical Operations, Project Management, Bio-analytical, Data Management, Biostatistics, Medical Writing, Quality Assurance and Regulatory and Medical Affairs services as well as clinical contract personnel services.

Source: Chiltern International

MORE ON THIS TOPIC